Chemed Corporation: Short-Term Headwinds But Long-Term Growth Potential

Chemed Corporation (CHE) is rated as a "buy" due to a significant 53.7% undervaluation, with a DCF intrinsic value of $744. Its unique diversification across VITAS hospice (63% of revenue) and Roto-Rooter plumbing (47%) provides a competitive advantage, evidenced by VITAS's 15.9% YOY adjusted EBITDA growth in Q1 2025 and consolidated EPS up 8.3%. However, the company faces considerable risk from VITAS's 94% Medicare revenue dependency and ongoing Medicare Cap limitations, alongside recent margin contraction in the Roto-Rooter segment attributed to rising labor costs.

Analysis

Chemed Corporation (CHE) presents a unique investment profile due to its diversified structure, operating both VITAS, a leading hospice care provider, and Roto-Rooter, a major plumbing and drain services company. This model provides a competitive advantage over pure-play healthcare peers like Amedisys (AMED) by diversifying revenue streams across uncorrelated industries. In Q1 2025, CHE demonstrated solid performance with an 8.3% year-over-year increase in consolidated adjusted EPS to $5.63. The VITAS segment was a key driver, with adjusted EBITDA growing 15.9% YoY, supported by geographic expansion. While Roto-Rooter's residential revenue grew a modest 1.7%, this was propped up by high-growth water excavation (+38%) and water restoration (+14%) services, which offset declines in core drain cleaning (-5.5%) and plumbing (-4.2%). Valuation appears attractive, with the company's forward P/E and EV/EBITDA multiples at the low end of its peer group and a DCF analysis suggesting a potential intrinsic value of $744 per share, a 53.7% premium to its current price. However, significant risks temper this outlook. The VITAS segment's heavy reliance on Medicare (94% of revenue) exposes it to regulatory headwinds, notably the Medicare Cap, which is expected to limit revenue by $18-25 million in 2025. Furthermore, the Roto-Rooter segment is facing margin contraction, with its adjusted EBITDA declining 2.4% due to rising labor costs and softening demand in certain residential areas.

Key Decisions for Investors

• Given the significant undervaluation suggested by the DCF analysis and low peer-relative multiples, investors could view the current price as an attractive entry point, capitalizing on the company's diversified business model and strong EPS.
• Investors must closely monitor regulatory news from the Centers for Medicare and Medicaid Services, as the profitability of the VITAS segment is highly sensitive to changes in the Medicare Cap, which remains a significant headwind.
• It is crucial to scrutinize the next earnings report for any stabilization in Roto-Rooter's margins and continued strength in its water restoration services, which are critical to offsetting rising labor costs and weakness in its core plumbing business.
• A comparative analysis against Amedisys should focus on Chemed's ability to maintain more stable EBITDA margins, which is the primary justification for its diversified strategy despite Amedisys reporting a higher EPS growth rate in the recent quarter.